<a href="https://laohu8.com/S/KNTPF">Kintor Pharmaceutical</a> Completes Patient Enrollment for Phase III Trial of KX-826 Tincture for Male AGA Treatment in China
Kintor Pharmaceutical Ltd. has announced the completion of patient enrollment in the Phase III stage of a pivotal clinical trial for KX-826 tincture 1.0%, aimed at treating male adult androgenetic alopecia (AGA) in China. The trial enrolled 666 patients and is characterized by a multi-center, randomized, double-blind, vehicle-controlled design. This Phase III stage involves a 24-week treatment period, followed by a 2-week safety observation period, across 25 clinical research centers in China. The Phase II stage of the trial previously met its primary endpoints, showing statistically significant and clinically meaningful outcomes in terms of efficacy and safety. The completion of the Phase III stage is anticipated by early 2026. Results from this stage have not yet been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kintor Pharmaceutical Ltd. published the original content used to generate this news brief on July 31, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。